Global Cancer Biomarkers Market 2015-2019

Global Cancer Biomarkers Market 2015-2019

About Cancer Biomarkers

Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Covered in this Report



TechNavio's report, Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA
Key Vendors
  • Abbott Laboratories
  • Affymetrix
  • Illumina
  • Qiagen
  • Quest Diagnostics
  • Roche Diagnostics
Other Prominent Vendors
  • Agendia
  • Agilent Technologies
  • Alere
  • Ambry Genetics
  • Amgen
  • Astellas Pharma US
  • Astex Pharmaceuticals
  • Atossa Genetics
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Biocurex
  • bioMérieux
  • Celldex Therapeutics
  • Clarient
  • diaDexus
  • DiagnoCure
  • Epigenomics
  • EUSA Pharma
  • Exact Sciences
  • Foundation Medicine
  • Fujirebio Diagnostics
  • Genomic Health
  • Geron
  • Immunomedics
  • Morphotek
  • Myriad Genetics
  • Nodality
  • Northwest Biotherapeutics
  • Ocimum Biosolutions
  • Oncothyreon
  • OriGene
  • Polymedco
  • Radient Pharmaceuticals
  • Randox Laboratories
  • Siemens Healthcare
  • US Biomarkers
  • Vermillion
Market Driver
  • Increased Prevalence of Cancer
  • For a full, detailed list, view our report
Market Challenge
  • Regulatory and Reimbursement Issues
  • For a full, detailed list, view our report
Market Trend
  • Growing Popularity of Companion Diagnostics
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global Cancer Biomarkers Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global Cancer Biomarkers Market: Abbott Laboratories, Affymetrix Inc., Illumina Inc., Qiagen NV, Quest Diagnostics and Roche Diagnostics.

Other Prominent Vendors in the market are: Agendia, Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US, Astex Pharmaceuticals, Atossa Genetics, Beckman Coulter, Becton, Dickinson and Co., Biocurex, bioMérieux, Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma, Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron, Immunomedics, Morphotek, Myriad Genetics, Nodality, Northwest Biotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers and Vermillion.

Commenting on the report, an analyst from TechNavio’s team said: “Growing popularity of companion diagnostics is one of the major trends emerging in this market. Pharmaceutical companies and diagnostic manufacturers are working together to develop such companion diagnostic tests.”

According to the report, the increased prevalence of cancer is one of the key drivers in this market. Globally, the prevalence of cancer is growing at a significant pace. According to researchers, a sedentary lifestyle, poor diet, smoking, and alcohol are among the key external factors contributing to the rise in new cancer cases each year. Some of the internal factors that contribute to the incidence of cancer include inherited mutations, hormonal imbalance, and mutations that occur from metabolism.

Further, the report states that one of the key challenges in the market is the poor regulatory and reimbursement systems. In most countries, regulatory and reimbursement procedures are not ideal to deal with molecular biomarker-based diagnostic tests. Poorly adapted regulatory and reimbursement systems act as a barrier to the inclusion of biomarker-based diagnostic tests in the clinical setting and may further hinder drug development

Companies Mentioned

Abbott Laboratories , Affymetrix , Illumina , Qiagen , Quest Diagnostics, Roche Diagnostics, Agendia , Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US , Astex Pharmaceuticals, Atossa Genetics , Beckman Coulter, Becton, Dickinson and Company,Biocurex, bioMérieux , Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma , Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron , Immunomedics, Morphotek, Myriad Genetics, Nodality, NorthwestBiotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers, Vermillion

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Cancer Biomarkers Market 2014-2019 (US$ billion)
    • Five Forces Analysis
  • Incidence and Prevalence
    • Table Incidence of Various Types of Cancer 2012
  • Biomarkers Used in Cancer Diagnosis
    • Cancer Biomarkers: FDA Approved Till 2012
    • Cancer Biomarkers: FDA Approved 2013
  • FDA Approval Process for Protein-based Cancer Biomarkers
    • Table FDA Classification of Medical Devices by Type of Class
  • Geographical Segmentation
    • Table Segmentation of Global Cancer Biomarkers Market by Geography 2014
    • Table Segmentation of Global Cancer Biomarkers Market by Geography 2019
    • Cancer Biomarkers Market in Americas
      • Market Size and Forecast
        • Table Cancer Biomarkers Market in Americas 2014-2019 (US$ billion)
      • Cancer Biomarkers Market in US
        • Table Cancer Biomarkers Market in US 2014-2019 (US$ billion)
    • Cancer Biomarkers Market in EMEA Region
      • Market Size and Forecast
        • Table Cancer Biomarkers Market in EMEA Region 2014-2019 (US$ billion)
    • Cancer Biomarkers Market in APAC Region
      • Market Size and Forecast
        • Table Cancer Biomarkers Market in APAC Region 2014-2019 (US$ billion)
        • Table Segmentation of Global Cancer Biomarkers Market by Geography 2014-2019
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Key Vendor Analysis 2014
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Abbott Laboratories
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Abbott Laboratories Inc.: Business Segmentation
      • Business Strategy
      • Revenue by Business Segmentation
        • Table Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
      • Revenue Comparison 2011 and 2012
        • Table Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
      • Revenue by Geographical Segmentation
        • Table Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
      • Key Information
      • SWOT Analysis
    • Affymetrix
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Affymetrix Inc.: Business Segmentation 2013
      • Business Segmentation by Revenue 2013
        • Table Affymetrix Inc.: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Affymetrix Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Affymetrix Inc.: Sales by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Illumina
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Illumina: Business Segmentation
      • Geographical Segmentation by Revenue 2013
        • Table Illumina: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Qiagen
      • Key Facts
      • Business Overview
      • Product Segmentation by Revenue 2013
        • Table Qiagen: Product Segmentation by Revenue 2013
      • Product Segmentation by Revenue 2012 and 2013
        • Table Qiagen: Product Segmentation by Revenue 2012 and 2013 (US$ million)
      • Geographical Segmentation by Revenue 2013
        • Table Qiagen: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Quest Diagnostics
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Global Cancer Biomarkers Market: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2011-2013
        • Table Global Cancer Biomarkers Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
      • Geographical Segmentation by Revenue 2013
        • Table Global Cancer Biomarkers Market: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Roche Diagnostics
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Roche Diagnostics: Business Segmentation by Revenue 2013
      • Geographical Segmentation by Revenue 2013
        • Table Roche Diagnostics: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook